27/01/2026
The proposed amendment to the MDR introduces targeted measures that have a direct impact on vigilance and post-market surveillance.
In this article, we analyse what changes at an operational level:
– PMS as an increasingly structured decision-making process
– new approaches to PSUR and PMCF
– recalibration of incident reporting timelines
– integration of cybersecurity and trend reporting
– concrete implications for manufacturers and service providers
A technical insight for professionals who work every day on medical device safety.
👉 https://safetydrugs.it/en/proposed-mdr-amendment-vigilance-and-post-market-surveillance/
In December 2025, the European Commission presented a proposal to amend Regulation (EU) 2017/745 (Medical Device Regulation, MDR) and, in parallel, Regulation (EU) 2017/746 (In Vitro Diagnostic Medical Devices Regulation, IVDR), with the aim of addressing a number of critical issues that have emerge...